Full Press Release Details
NATICK, Mass. , Oct. 28, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful innovation to clinicians and patients through a robust schedule of sponsored research presentations at the 25 th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, October 27 – November 2 in San Francisco.
The clinical presentations will provide new insights into Boston Scientific research and therapy advances in coronary and peripheral artery disease, including aortic valve disease, coronary artery disease and hypertension.
"The industry-leading technologies we will be discussing at TCT showcase our commitment to bringing value-driven solutions that improve outcomes, enhance the patient experience and lower healthcare costs," said Keith Dawkins , M.D., chief medical officer, Boston Scientific. "These technologies are the result of world-wide physician collaboration that underscores our commitment to advancing cardiology together."
Schedule of Events All programs are Pacific Time, with events held at the Moscone Center unless otherwise indicated.
Monday, October 28
Tuesday, October 29
Thursday, October 31
Conference attendees and media are invited to visit the Boston Scientific "Advancing Cardiology Together" exhibit at booth 1817 in the Main Exhibit Hall. Media attending TCT can also arrange to tour the Boston Scientific Technology Suite on Wednesday, October 30 from 4 p.m. to 5 p.m. , South Hall, Suites 30-31.
The Lotus, Vessix, WATCHMAN and Innova devices are investigational devices and not available for sale in the U.S.
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook .
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
CONTACT: Ryan Davenport 763-494-2664 (office) Global Media Relations Boston Scientific Corporation [email protected]
Michael Campbell 508-650-8023 (office) Investor Relations Boston Scientific Corporation [email protected]
SOURCE Boston Scientific Corporation